On March 17, 2023 Jacobio Pharmaceuticals reported the company has received IND (Investigational New Drug) approval of its self-developed drug GUE inhibitor JAB-24114 from the Center for Drug Evaluation (CDE) of China (Press release, Jacobio Pharmaceuticals, MAR 17, 2023, View Source [SID1234644981]). Jacobio plans to initiate a Phase I/IIa clinical trial in the China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways such as TCA cycles, nucleotide synthesis, purine synthesis and amino acid synthesis. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. Preclinical in vivo study exhibited that JAB-24114 can effectively inhibit tumor growth in multiple animal models.
JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors. Jacobio has self-developed SHP2 inhibitors (JAB-3312 and JAB-3068), KRAS G12C inhibitor Glecirasib (JAB-21822), and KRASmulti inhibitor (JAB-23400), which have potential to provide more combination therapies to patients.
Jacobio is committed to developing global first-in-class drugs, and key programs are targeting among the top three worldwide. Currently there is only one program in the Phase I clinical stage in respective drug class globally.